Azole-resistant Aspergillus fumigatus due to TR46/Y121F/T289A mutation emerging in Belgium, July 2012

Eurosurveillance

Volumn 17, Issue 48, 2012, Pages

  Vermeulen, E ^a   Maertens, J ^b   Schoemans, H ^b   Lagrou, K ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CYTOCHROME P450; GALACTOMANNAN; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ADULT; ANTIFUNGAL RESISTANCE; ARTICLE; ASPERGILLUS FUMIGATUS; BELGIUM; CASE REPORT; CENTRAL NERVOUS SYSTEM ASPERGILLOSIS; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DYSPNEA; FEVER; GENE MUTATION; HUMAN; INVASIVE ASPERGILLOSIS; LUNG ASPERGILLOSIS; LUNG LAVAGE; MALE; MINIMUM INHIBITORY CONCENTRATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL (TOPIC); THORAX PAIN;

EID: 84870770570     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813-21.
2. Espinel-Ingroff A, Diekema DJ, Fothergill A, Johnson E, Pelaez T, Pfaller MA, et al. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J Clin Microbiol. 2010;48(9):3251-7.
3. Pfaller M, Boyken L, Hollis R, Kroeger J, Messer S, Tendolkar S, et al. Comparison of the broth microdilution methods of the European Committee on Antimicrobial Susceptibility Testing and the Clinical and Laboratory Standards Institute for testing itraconazole, posaconazole, and voriconazole against Aspergillus isolates. J Clin Microbiol. 2011;49(3):1110-2.
4. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Antifungal Agents-breakpoint tables for interpretation of MICs. 2012; version 4.1. Växjö: EUCAST. 14 Mar 2012. Available from:http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/AFST/Antifungal_breakpoints_v_4.1.pdf
5. Jeans AR, Howard SJ, Al-Nakeeb Z, Goodwin J, Gregson L, Majithiya JB, et al. Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints. J Infect Dis. 2012;206(3):442-52.
6. Snelders E, Karawajczyk A, Schaftenaar G, Verweij P, Melchers WJG. Azole Resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. Antimicrob Agents Chemother. 2010;54(6):2425-30.
7. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of filamentous fungi: approved standard. 2nd ed. M38-A2 Vol. 28 No. 16. Wayne (Pensylvania): CLSI; 2008.
8. Alanio A, Sitterlé E, Liance M, Farrugia C, Foulet F, Botterel F, et al. Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies. J Antimicrob Chemother. 2011;66(2):371-4.
9. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106(10):2258-66.
10. Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van Wijngaerden E. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med. 2004;170(6):621-5.
11. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(3):327-60.
12. Howard SJ, Cerar D, Anderson MJ, Albarrag A, Fisher MC, Pasqualotto AC, et al. Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis. 2009;15(7):1068-76.
13. Snelders E, van der Lee HA, Kuijpers J, Rijs AJ, Varga J, Samson RA, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 2008;5(11)e219:1629-37.
14. Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis. 2009;9(12):789-95.
15. Van der Linden JWM, Arendrup MC, Verweij PE, SCARE network. Prospective international surveillance of azole resistance in Aspergillus fumigatus: SCARE-Network. In: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2011 Sep 17-20; Chicago, IL. Abstract M-490.
16. Lockhart SR, Frade JP, Etienne KA, Pfaller MA, Diekema DJ, Balajee SA. Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob Agents Chemother. 2011;55(9):4465-8.
17. Chowdhary A, Kathuria S, Randhawa HS, Gaur SN, Klaassen CH, Meis JF. Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J Antimicrob Chemother. 2012;67(2):362-6.
18. Camps SMT, van der Linden JWM, Melchers WJG, Verweij PE. A new resistance mechanism emerging in clinical Aspergillus fumigatus isolates in The Netherlands. In: 5th TIMM, Valencia, Spain, 2011, Abstract O3.2.
19. Howard SJ, Arendrup MC. Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection. Med Mycol. 2011;49 Suppl 1:S90-5.